VENCLYXTO®▼ (venetoclax) in Acute Myeloid Leukaemia (AML)
In combination with a hypomethylating agent for newly-diagnosed patients with AML who are ineligible for intensive chemotherapy1
UK-VNCAML-220109 | April 2022
1. Venclyxto Summary of Product Characteristics
FRONTIERS promotional meetings are fully funded and organised by AbbVie for UK healthcare professionals. UK-VNCAML-220031 | April 2022.
UK-VNCAML-220256. Date of Preparation: February 2023.
UK-VNCAML-220206. Date of Preparation: November 2022.
VENCLYXTO is a BCL-2 inhibitor licensed for the treatment of AML across all mutational subtypes1
VENCLYXTO in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy
VENCLYXTO in combination with obinutuzumab (Ven+O) is indicated for the treatment of adult patients with previously untreated CLL
VENCLYXTO in combination with rituximab (Ven+R) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy
VENCLYXTO is licensed as monotherapy (Ven mono), for the treatment of adult patients with CLL:
- in the absence of del(17p) or TP53 mutations and who have failed both chemoimmunotherapy and a BCRI
- in the presence of del(17p) or TP53 mutations and who are either unsuitable for, or have failed a BCRI
AML=acute myeloid leukemia; BRCI=B-cell receptor pathway inhibitor; CLL=chronic lymphocytic leukaemia
References
- VENCLYXTO Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
UK-VNCAML-220205. Date of preparation: November 2022.
